Tumor Markers in Small Cell Lung Cancer
Author Information
Author(s): P.W.M. Johnson, S.P. Joel, S. Love, M. Butcher, M.R. Pandian, L. Squires, P.F.M. Wrigley, M.L. Slevin
Primary Institution: ICRF Department of Medical Oncology, St Bartholomew's Hospital
Hypothesis
Can tumor markers predict survival and monitor remission in small cell lung cancer?
Conclusion
Neurone-specific enolase (NSE) is a significant predictor of survival and remission duration in small cell lung cancer.
Supporting Evidence
- 81% of patients had elevated NSE levels at presentation.
- Patients with NSE below twice the upper limit of normal had a median survival of 15 months.
- Rising NSE levels during chemotherapy correlated with shorter remission duration.
- 52% of patients had rising ChrA levels before clinical evidence of disease recurrence.
Takeaway
Doctors measured certain markers in the blood of lung cancer patients to see if they could tell how long patients would live or if the cancer would come back.
Methodology
Blood samples were taken from patients at various stages of treatment to measure levels of NSE, LDH, ChrA, and CEA.
Potential Biases
Patients were selected based on their ability to consent and have samples stored, which may not represent the general population.
Limitations
The study only included patients from a single center and those who consented to have samples stored.
Participant Demographics
Of the 154 patients, 65% were male, with ages ranging from 34 to 77 and a median age of 63.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website